Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
19.97
-2.55 (-11.32%)
At close: Apr 4, 2025, 4:00 PM
21.00
+1.03 (5.16%)
After-hours: Apr 4, 2025, 7:35 PM EDT

Company Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.

It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.

It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases.

The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals logo
Country United States
Founded 2009
IPO Date Nov 9, 2017
Industry Biotechnology
Sector Healthcare
Employees 710
CEO Cedric Francois

Contact Details

Address:
100 Fifth Avenue
Waltham, Massachusetts 02451
United States
Phone 617 977 5700
Website apellis.com

Stock Details

Ticker Symbol APLS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001492422
CUSIP Number 03753U106
ISIN Number US03753U1060
Employer ID 27-1537290
SIC Code 2834

Key Executives

Name Position
Dr. Cedric Francois M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Alec Machiels J.D., MBA Co-Founder and Director
Timothy E. Sullivan Chief Financial Officer and Treasurer
David O. Watson Esq., J.D. General Counsel
Dr. Caroline R. Baumal M.D. Chief Medical Officer
Dr. Pascal Deschatelets Ph.D. Co-Founder and Chief Scientific Officer
James G. Chopas CPA Vice President, Corporate Controller and Chief Accounting Officer
Meredith Kaya Senior Vice President, Investor Relations and Strategic Finance
Prof. Peter Hillmen M.D., Ph.D. Head of Hematology Engagement and Member of PNH Scientific Advisory Board
Victoria L. Brown Senior Vice President

Latest SEC Filings

Date Type Title
Mar 17, 2025 144 Filing
Mar 5, 2025 144 Filing
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2025 10-K Annual Report
Feb 11, 2025 144 Filing
Feb 10, 2025 SCHEDULE 13G/A Filing
Feb 3, 2025 SCHEDULE 13G Filing
Jan 29, 2025 144 Filing
Jan 29, 2025 144 Filing
Jan 29, 2025 144 Filing